Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540346 | 1.00 | BACE1 (0.38) | BACE1ALDH1A1NPC1TP53RAB9A | |
| SCHEMBL6541213 | 0.93 | BACE1 (0.39) | BACE1ALDH1A1NPC1TP53RAB9A | |
| SCHEMBL6541210 | 0.93 | BACE1 (0.39) | BACE1ALDH1A1NPC1TP53RAB9A | |
| SCHEMBL6540750 | 0.92 | BACE1 (0.35) | BACE1ALDH1A1NPC1TP53RAB9A | |
| SCHEMBL6540758 | 0.92 | BACE1 (0.35) | BACE1ALDH1A1NPC1TP53RAB9A | |
| SCHEMBL6540274 | 0.89 | ADRB3 (0.42) | BACE1ADRB3ADRB1 | |
| SCHEMBL6540282 | 0.89 | ADRB3 (0.42) | BACE1ADRB3ADRB1 | |
| SCHEMBL6540953 | 0.88 | BACE1 (0.39) | BACE1ADRB3ADRB1ADRB2NAMPT | |
| SCHEMBL6540643 | 0.88 | BACE1 (0.39) | BACE1ADRB3ADRB1ADRB2NAMPT | |
| SCHEMBL6540949 | 0.88 | BACE1 (0.39) | BACE1ADRB3ADRB1ADRB2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | BACE1 3900/4885ALDH1A1 188/4885NPC1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.